Posters & Presentations
Lasofoxifene (LAS) Plus Abemaciclib (Abema) for Treating ESR1-mutated ER+/HER2- Metastatic Breast Cancer (mBC) after Progression on Prior Therapies: ELAINE 2 Study Update
DOWNLOAD
Lasofoxifene (LAS) Plus Abemaciclib (Abema) for Treating ESR1-mutated ER+/HER2- Metastatic Breast Cancer (mBC) after Progression on Prior Therapies: ELAINE 2 Study Update
DOWNLOAD
Dr. Gal-Yam’s presentation from MBCRC 2022
WATCH NOW
(Trial in Progress) A phase 2, open-label, randomized multicenter trial to evaluate neoadjuvant lasofoxifene in molecularly-selected HR+/HER2- Clinical Stage 2/3 breast cancer
DOWNLOAD
Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
DOWNLOAD
Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined with Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies
DOWNLOAD
Vaginal/Vulvar Symptoms with Lasofoxifene Versus Fulvestrant in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer Patients
DOWNLOAD
Knowledge of Tumor/Blood Genomic Testing (NGS) and ESR1 Mutations in a Survey of Patients with ER+/HER2- Metastatic Breast Cancer (mBC)
DOWNLOAD
Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene or fulvestrant in the ELAINE 1 study
DOWNLOAD
Lasofoxifene Reduced ESR1 Mutant Allele Fraction and Provided Clinical Benefit versus Fulvestrant in Metastatic Breast Cancer: the ELAINE 1 trial
DOWNLOAD
Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
DOWNLOAD
Durable Complete Remission of Metastatic ER+/HER2− Breast Cancer after Lasofoxifene Therapy
DOWNLOAD
Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined with Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies
DOWNLOAD
Lasofoxifene as a Potential Treatment for Aromatase Inhibitor Resistant ER+ Breast Cancer
DOWNLOAD
Lasofoxifene alone or in combination with palbociclib is an effective treatment for therapy-resistant ER-positive metastatic breast cancer
DOWNLOAD
Patient Knowledge, Attitudes and Perceptions Regarding Breast Cancer Biomarkers, Testing, and Quality of Life
DOWNLOAD
A Preliminary Assessment of Knowledge, Attitudes, and Awareness Surrounding Precision Medicine, ESR1 Mutations, and Biomarker Testing Amongst Medical Oncologists
DOWNLOAD
An Open-label, Randomized, Multi-center Phase 2 Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation
DOWNLOAD
Lasofoxifene Decreases Breast Cancer Lung and Liver Metastasis in a Mammary Intraductal (MIND) Xenograft Model of Mutant ERa+ Breast Cancer
DOWNLOAD
Physician Perceptions of Estrogen Agonist/Antagonists in Menopausal Health: A Survey to Address Osteoporosis, Urogenital Health and Breast Concerns in Menopause and Breast Cancer Survivorship
DOWNLOAD
A Preliminary Assessment of Knowledge, Attitudes, and Awareness Surrounding Precision Medicine, ESR1 Mutations, and Biomarker Testing Amongst Medical Oncologists
DOWNLOAD
Lasofoxifene 0.25 mg Compared with Raloxifene 60 mg for Effects on Bone Mineral Density and Markers of Bone Turnover: Results from the Phase 3 Comparison of Raloxifene and Lasofoxifene (CORAL) Trial
DOWNLOAD
Lasofoxifene, an Estrogen Agonist/Antagonist, Improves Symptoms of Genitourinary Syndrome and Menopause (GSM) and Physiologic Markers Associated with Vulvovaginal Atrophy (VVA) in Two Large Phase 3 Studies
DOWNLOAD